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METHODOLOGY
The OncoLifeS data-biobank for oncology: 
a comprehensive repository of clinical 
data, biological samples, and the patient’s 
perspective
Grigory Sidorenkov1, Janny Nagel1, Coby Meijer2, Jacko J. Duker3, Harry J. M. Groen4, Gyorgy B. Halmos5, 
Maaike H. M. Oonk6, Rene J. Oostergo1, Bert van der Vegt3, Max J. H. Witjes7, Marcel Nijland8, Klaas Havenga9, 
John H. Maduro10, Jourik A. Gietema2 and Gertruida H. de Bock1*
Abstract 
Background: Understanding cancer heterogeneity, its temporal evolution over time, and the outcomes of guided 
treatment depend on accurate data collection in a context of routine clinical care. We have developed a hospital-
based data-biobank for oncology, entitled OncoLifeS (Oncological Life Study: Living well as a cancer survivor), that links 
routine clinical data with preserved biological specimens and quality of life assessments. The aim of this study is to 
describe the organization and development of a data-biobank for cancer research.
Results: We have enrolled 3704 patients aged ≥ 18 years diagnosed with cancer, of which 45 with hereditary breast-
ovarian cancer (70% participation rate) as of October 24th, 2019. The average age is 63.6 ± 14.2 years and 1892 (51.1%) 
are female. The following data are collected: clinical and treatment details, comorbidities, lifestyle, radiological and 
pathological findings, and long-term outcomes. We also collect and store various biomaterials of patients as well as 
information from quality of life assessments.
Conclusion: Embedding a data-biobank in clinical care can ensure the collection of high-quality data. Moreover, the 
inclusion of longitudinal quality of life data allows us to incorporate patients’ perspectives and inclusion of imaging 
data provides an opportunity for analyzing raw imaging data using artificial intelligence (AI) methods, thus adding 
new dimensions to the collected data.
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Background
Cancer is mainly considered an age-related disease [1], 
with more than half of all cancers diagnosed in people 
older than 70 years [2]. As life expectancy has increased, 
so too have the incidence and mortality of cancer, result-
ing in cancer becoming a leading cause of death in 
many European countries [3]. Indeed, cancer has now 
overtaken cardiovascular disease as the main cause of 
death in twelve of these countries [3].
Cancer is a complex disease with more than 1 mil-
lion known genotypes [4]. Patients with cancer often 
differ genotypically and phenotypically [5], resulting in 
marked variabilities in the required management and 
treatment response. Therefore, personalized treatment 
approaches are increasingly being used for specific can-
cers. Although randomized clinical trials (RCTs) are gen-
erally considered the best approach for evaluating such 
treatment approaches, primarily because they reduce the 
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generalizability [6, 7]. An alternative source of relevant 
information is observational research [8, 9].
Observational study involves collecting routine clini-
cal data about carefully selected patient groups, and this 
can be combined with genetics and omics data from bio-
logical specimens [10]. Indeed, understanding cancer 
heterogeneity, its temporal evolution over time, and the 
outcomes of guided treatment depend on accurate data 
about patient characteristics and their clinical manage-
ment. Linking these routine clinical data to preserved 
biological specimens can then enable reproducible 
research capable of discovering biomarkers of cancer 
and/or treatment response, evaluating personalized 
treatment approaches, and increasing patient awareness 
[11]. Including quality of life assessments may provide 
relevant information on how cancer and its treatment 
affects the subjective well-being of patients.
We have established a hospital-based data-biobank, 
entitled OncoLifeS (Oncological Life Study: Living well 
as a cancer survivor) to link routinely collected clinical 
data with preserved biological specimens and quality of 
life assessments. The OncoLifeS data-biobank has been 
designed to facilitate cancer research by providing clear 
phenotypic and genotypic data in a clinical context.
Results
Current state of the OncoLifeS data‑biobank
As of October 24th, 2019, we had included 3704 patients 
with cancer in the OncoLifeS data-biobank (Table  1). 
The average age at inclusion was 63.6 ± 14.2  years and 
1892 are females (51.1%). To date, most patients (82.6%) 
have been included by the three largest tumor working 
groups, with gynecological oncology contributing 24.6%, 
lung oncology contributing 22.4%, and head and neck 
oncology contributing 35.6%. We have also included 45 
patients diagnosed with hereditary breast-ovarian can-
cer (average age, 36.5 ± 11.3 years Four papers using the 
data of OncoLifeS has been published in 2019 in peer-
reviewed journals so far [12–15].
We anticipate that approximately 1500 patients will be 
included in the data-biobank each year from 2019, with 
the total size therefore expected to reach 10,000 partici-
pants by 2023. Overall, about 70% of approached patients 
have agreed to participate, with the estimated participa-
tion rate per tumor working group between 2017 and 
2018 shown in Table  1. The other 30% of patients were 
either not asked or refused to participate, and although 
the exact numbers are unknown, most of these were not 
asked. To date, 34 patients (1%) have withdrawn their 
informed consent. Patient-reported data, including data 
about quality of life, are collected for about 70–80% of 
patients depending on a tumor group. The examples 
of quality of life [12, 14] and imaging [15] data analysis 
could be found in previous studies.
Composition of the three largest groups
Of the three largest groups, patients from the head and 
neck oncology group are the oldest, having a mean age of 
68.9 ± 11.9 years at baseline. In this group, more than 50% 
of the included patients have stage III or IV cancer, with 
50% undergoing surgery, 25% undergoing radiotherapy, 
and 12% undergoing chemotherapy. Biomaterials are avail-
able for more than 40% of these patients. The imaging data 
are available for all patients in this group, except those 
with very small tumors (T1a) and very small skin cancers.
In the lung oncology group, the average age was 
64.5 ± 9.9 years at baseline, with most (90%) having stage 
III or IV non-small cell lung cancer. More than 70% of the 
patients in this group received chemotherapy and 40% 
received radiotherapy; however, only 25% underwent 
surgery. Biomaterials are available for more than 80% of 
these patients. The imaging data are available for 95% of 
patients in this group.
In the gynecological oncology group, the average age 
was 62.5 ± 14  years at baseline, half of all patients have 
ovarian carcinoma, and 40% have stage III or IV disease. 
The rates of surgery, radiotherapy, and chemotherapy in 
this group are 77%, 20%, and 17%, respectively. Biomate-
rials are available for 80% of these patients. The imaging 
data are available for 95% of patients in this group.
Discussion
The OncoLifeS data-biobank was established in 2014 to 
provide an infrastructure for clinical cancer research, to 
facilitate translational research toward more personal-
ized cancer care, and to monitor oncological quality of 
Table 1 Participation in  the  OncoLifeS data-biobank 
by tumor working group
Number of patients included and participation rate for a 2 years period 
(2017–2018)
a Not available, as these groups did include since 2019





Gynecological oncology 910 94%
Lung oncology 831 64%
Testicular oncology 98 100%
Head and neck oncology 1319 64%
Medical oncology/immunotherapy 77 a
Hematological oncology 343 a
Neuro-endocrine oncology 45 a
Bone and soft-tissue oncology 36 a
Hereditary breast-ovarian cancer 45 a
Total 3704
Page 3 of 9Sidorenkov et al. J Transl Med          (2019) 17:374 
care outcomes. At the time of writing, we have already 
established a sizable data-biobank, and this is continu-
ing to grow. The process of building a data-biobank is 
rarely described and even less often published in peer-
reviewed journals, where it can be critically evaluated 
by external reviewers. We have demonstrated the fea-
sibility of data-biobank building with a relatively low 
budget by collecting data in routine clinical care. The 
infrastructure required for the data-biobank has been 
described, including the procedures needed for data 
collection, handling, storage, and access. The data from 
OncoLifeS are managed and available for research pur-
poses according to findable, accessible, interoperable, 
and re-usable principles [16].
The extensive data in the OncoLifeS data-biobank 
provides many opportunities for researchers to study 
cancer at molecular and clinical levels. This includes 
disease etiology, disease processes, response to cancer 
treatment (including longitudinal quality of life data), 
and the short- and long-term side-effects of treat-
ment. Five of the main benefits and potential uses of 
the OncoLifeS initiative are worthy of note. First, the 
data-biobank covers uncommon cancers and does not 
focus solely on major cancer types. Second, observa-
tional studies based on OncoLifeS data can be used to 
evaluate the impact of clinical interventions on quality 
of life. The quality of life data collected over multiple 
time points in the follow up provides relevant informa-
tion on subjective patients well-being in the course of 
treatment and cancer progression. Third, the data can 
be used to identify molecular and imaging biomarkers 
that can predict a range of outcomes, such as disease 
progression and response to various treatments. Avail-
ability of raw imaging data linked to other clinical data 
and biological specimens is a unique features of the 
OncoLifeS, allowing application of Artificial intelli-
gence (AI) methods for diagnostic and cancer progres-
sion research. Fourth, this data-biobank can facilitate 
translational research and investigations into the course 
of cancer after a given treatment, thereby helping to 
identify risk or protective factors, and helping with 
post-marketing surveillance. Fifth, we can infer trends 
in health care and related costs from the data.
The OncoLifeS data-biobank is embedded in a large 
academic hospital, which ensures structured data storage 
and management, with continued adherence to high legal 
and ethical standards. Other studies falling under the 
scope of the “Dutch Medical Research Involving Human 
Subject Act (WMO 1998)” can adopt the methods of 
the OncoLifeS initiative for data collection, data stor-
age, and biomaterial collection and processing, provided 
they have appropriate governance procedures and ethical 
approvals in place.
We included a population of consecutive people diag-
nosed either with cancer or with a genetically increased 
risk of cancer. To improve the relevance to future 
research, we collected important contextual data with the 
biological samples, such as patient-reported history, qual-
ity of life, and outcomes. The OncoLifeS initiative also 
involves health care providers in data collection, thereby 
maintaining continued data access and engagement in 
research. This facilitates interpretation of research in a 
clinical context and could optimize care regimens [17]. 
In contrast to RCT designs, which include highly selected 
patient populations, our design can provide more gener-
alizable and clinically relevant conclusions [8].
Advances in omics methodologies and big-data analyt-
ics in cancer research have led to the emergence of sev-
eral cancer data-biobanks in Europe and worldwide [18, 
19]. Most of these collect DNA, blood, and tissue sam-
ples, and/or are specific to a particular cancer or prob-
lem (e.g., biomarker discovery). However, few have been 
linked to clinical data including medical imaging data. 
In the Netherlands, relevant biobanks are the BOSOM, 
Maastricht UMC, ORIGO Leiden, the vUMC, and Parels-
noer biobanks, with focuses on breast cancer, head and 
neck cancer, and colorectal and gastric cancers. Other 
biobanks include data and tissue collections from big 
clinical trials (e.g., the TUMOROID trial and the TripleB 
study) [20]. The Radboud Biobank from Nijmegen is per-
haps most comparable to the OncoLifeS data-biobank, 
providing access to both biological specimens and linked 
clinical data [21].
Unlike its predecessors, a notable strength of the 
OncoLifeS data-biobank is that it includes longitudinal 
quality of life data that will allow patient perspectives to 
be incorporated in research. Moreover, the OncoLifeS 
data provide an opportunity to analyze raw imaging 
data (e.g., computed tomography images) in the rapidly 
developing field of quantitative imaging (radiomics). 
Other strengths include the systematic and routine col-
lection of clinical and socioeconomic data that are linked 
to collected biological specimens. These specimens are 
often collected and stored without a structured proto-
col and often vary in quality due to the myriad of factors 
that influence the collection, processing, and storage of 
specimens [22, 23]. Our strict protocols for sampling, 
handling, and storage moderate these factors. Moreo-
ver, routine clinical and/or radiological data are often not 
available or are not linked to specimens in data-biobanks. 
Therefore, data-biobanks that have standardized and 
established procedures, such as OncoLifeS, can be linked 
to other trusted data, thereby improving research collab-
oration and the quality of cancer research.
The continued functioning of any data-biobank 
requires funding to cover infrastructure and personnel 
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costs. Although the OncoLifeS data-biobank is cur-
rently supported by the University Medical Center Gro-
ningen (UMCG), there is no guarantee that this funding 
will continue in the future. To cover its operational 
costs, the OncoLifeS must therefore attract the interest 
and collaboration of other researchers, institutions, and 
businesses. Collaboration is being promoted through 
the Groningen Data Catalogue [24], Biomarker Bay 
[25], and by the Biobanks and Biomolecular Resources 
Research Infrastructure in the Netherlands [20]. Thank-
fully, a straightforward administrative process makes the 
OncoLifeS data-biobank easy to access, which will facili-
tate collaboration.
Our data-biobanking model ensures that high-qual-
ity clinical data linked to biomaterial are available for 
translational research. The data-biobank respects the 
requirements of the European General Data Protec-
tion Regulation with methods of data collection. and 
anonymization, together with the consent requirements, 
allowing data use for analysis. Data from the OncoLifeS 
initiative can be used to evaluate and improve treat-
ment for patients who may otherwise never be included 
in clinical trials, providing additional information across 
a broader spectrum of conditions when compared with 
other data-biobanks. We plan to expand the data col-
lection to include not only unstructured (free text) data 
from hospital records but also to add more details about 
comorbidities. Finally, we also plan to extend the patient-
reported outcomes to include measures of pain, fatigue, 
sleep, depression and anxiety, and the ability to partici-
pate in social roles and activities [26].
Methods
Aims
The primary aims of the current work were to describe 
the organization and process of starting our data-biobank 
of clinical data, biological samples, and quality of life 
assessments in a clinical setting. We also present some 
preliminary results to demonstrate the feasibility of this 
data-biobank. Overall, however, we seek to provide guid-
ance on how to set up and run a successful data-biobank 
by describing our experiences.
Setting
The OncoLifeS data-biobank has been embedded within 
the structure of the UMCG, an academic, medical, ter-
tiary referral center in the north of the Netherlands, 
covering an area with 3.4 million inhabitants. Oncologi-
cal care within the UMCG is provided by multidiscipli-
nary tumor working groups that include the specialists 
needed to provide optimally personalized cancer care. 
The UMCG has 16 different tumor working groups that 
manage both low- and high-volume tumors. Treatment 
decisions are supported by a weekly molecular tumor 
board focusing on DNA, RNA, and protein aberrations, 
using novel technology to predict the added value of tar-
geted therapy. The OncoLifeS initiative was established 
by the Cancer Research Center of the Comprehensive 
Cancer Center and the Department of Epidemiology in 
close cooperation with the 16 tumor working groups.
The UMCG is an internationally and nationally rec-
ognized expert center for several rare tumors, including 
head and neck, neurological and neuroendocrine, soft-
tissue and bone, gynecological, esophageal and gastric, 
testicular germ-cell, and some hereditary cancers, as 
well as mastocytosis and mucosa-associated lymphoid 
tissue (MALT) lymphoma related to Sjögren syndrome. 
The UMCG is a partner of the European reference net-
work on rare cancers (EURACAN), and is active in four 
domains: sarcoma, neuroendocrine tumors, rare gyneco-
logical tumors, and testicular germ-cell tumors [27]. At 
the UMCG, we also offer specialist care to patients with 
lung cancer who require targeted treatment and we serve 
as a reference center for cases of acute myeloid leukemia 
requiring intensive treatment.
Design
Inclusion in the OncoLifeS data-biobank is prospective 
and on an ongoing basis. All adult patients (age > 18 years) 
diagnosed with cancer or with a genetically increased risk 
of cancer are included, without further exclusion crite-
ria. Informed consent is obtained from patients before 
inclusion, and the data collection processes are embed-
ded in routine care. All relevant processes are described 
with standard operating procedures to ensure that the 
data-biobank is of high quality. Established in 2014, the 
data-biobank first began with the inclusion of patients 
diagnosed with head and neck cancer (October 2014), 
but we soon included patients diagnosed with lung can-
cer (October 2015) and gynecological cancer (January 
2016). After a 3-year consolidation period, other tumor 
working groups have started to participate, including 
those for testicular, hematological, brain, and neuroendo-
crine cancers, and those covering specific patients (e.g., 
immunotherapy-treated, adolescent, and young adult 
groups).
Data protection and regulation
Currently, no specific law in the Netherlands governs 
data-biobanking, and the OncoLifeS initiative does 
not fall under the scope of the Dutch Medical Research 
Involving Human Subject Act (WMO), 1998. We there-
fore followed the national guideline “Human Tissue 
and Medical Research: code of conduct for responsible 
use (2011)” [28], the internal UMCG guidance for data-
biobanking (not published; available internally in Dutch 
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only), and the requirements of the European General 
Data Protection Regulation for scientific research. The 
data-biobank is being coordinated by a manager (GHdB), 
coordinator (JN), steering committee (see author list), 
and independent scientific board (see acknowledgment). 
Representatives of each participating tumor working 
group are included in both the steering committee and 
the scientific board.
The OncoLifeS initiative has been approved by the 
medical ethics committee of the UMCG (no. 2010/109) 
and has been ISO certified (9001:2008 Healthcare). It was 
registered in the Dutch Trial Register under the number: 
NL7839.
Informed consent
When patients are invited for a clinical visit, they receive 
an information leaflet about the OncoLifeS initiative. 
At their first visit, a physician, nurse practitioner, or a 
(research) nurse further informs the patient about the 
OncoLifeS data-biobank and asks if they are willing to 
participate. If the patient agrees, his or her written con-
sent is obtained for each of the following: (1) to use all 
clinical, patient, tumor, treatment, and outcome data; (2) 
to collect biomaterials; (3) to collect clinically relevant 
patient-reported data (e.g., data on lifestyle and quality 
of life); (4) to store data and biomaterial infinitely; (5) to 
obtain data from other sources (e.g., general practition-
ers, pharmacists, and other hospitals); (6) to link with 
other data(bio)bases (e.g., municipal registration, Cen-
tral Bureau for Statistics, the Netherlands Comprehen-
sive Cancer Center, the nationwide registry of histo- and 
cytopathology in the Netherlands, and LifeLines (a large 
cohort study of a random sample of 10% of inhabitants in 
the north of the Netherlands) [29]; (7) to allow research 
to improve outcome of cancer treatment and living as a 
cancer survivor; (8) to use residual tissue, bone marrow, 
and blood samples; (9) to allow collaboration between 
medical doctors and national or international organiza-
tions/companies; and (10) to publish results in scientific 
journals. Patients are also asked to give their permission 
to be contacted during follow-up either by researchers 
if additional data is needed or by a physician if there are 
unanticipated clinically relevant findings. Participants are 
informed that they retain the right to withdraw their con-
sent at any stage.
Data and biomaterial collection
Clinical data are collected by physicians during routine 
clinical care. This data includes patient characteristics, 
comorbidities, oncological diagnosis and staging, diag-
nostic details (e.g., pathology reports and radiological 
images), and treatments (see Table  2). Baseline data are 
retrieved from the hospital’s electronic health care record 
system (Epic, Epic Systems Corporation, Verona, WI). 
Data concerning tumor stage (TNM staging is according 
to the International Classification of Diseases for Oncol-
ogy) and cancer treatment is confirmed by the different 
participating multidisciplinary tumor working groups. A 
comparable approach has successfully been used by the 
UMCG family cancer clinic for patients at increased risk 
of breast and ovarian cancer [30].
Patient-reported data are collected via questionnaire at 
baseline (see Table 3), including data on family history of 
cancer, lifestyle, social status, quality of life, and comor-
bidities. For patients aged 65  years and older, we also 
include evaluations of daily living activities and frailty. 
The baseline questionnaires are sent to participants by 
post or email within one week of gaining informed con-
sent. Data on quality of life are collected by questionnaire 
at baseline and at 6, 12, 18, and 24 months after the start 
of treatment.
Several biomaterials are routinely collected during clin-
ical care. The following are collected and stored for future 
use: serum, heparin-plasma, heparin-plasma (for cell iso-
lation) ethylenediaminetetraacetic acid (EDTA) plasma, 
+ buffy coat (DNA), Genomic DNA (by whole blood 
Table 2 Clinical data collected from the electronic medical 
records of the hospital





Clinical history Comorbidity, Clinical history of 
cancer management
Comorbidity The Adult Comorbidity Evaluation 
27 (ACE-27) score






Intention to treat (curative/pal-
liative)
Recurrences
Follow-up status (status dead or 
alive) and related date
Surgical treatment Type of surgery
Date of surgery
Radiotherapy Type of radiotherapy
Date of start radiotherapy
Date of end radiotherapy
Number of fractions and Gy per 
fraction
Systemic therapy Type of treatment
Date of start treatment
Date of end treatment
Scheme of treatment
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collected in EDTA tubes), plasma for cell-free DNA (by 
whole blood collected in Streck tubes), RNA (by whole 
blood collected in PAXgene tubes), bone marrow, feces, 
urine, tumor tissue, and tissue adjacent to a tumor (see 
Table 4).
During follow-up, we have sought to include long-term 
outcome data regarding response to cancer treatment, 
treatment complications (including side-effects), recur-
rence, new cancers, disease-specific survival, overall sur-
vival, and patient-reported quality of life. Patient survival 
is evaluated monthly by linkage to municipal death reg-
istrations. Data from the OncoLifeS data-biobank can 
also be linked to other sources of data to gain insights 
into outpatient medicine used (e.g., pharmacy data), and 
treatment outcomes (e.g., survival in years), which can 
provide long-term outcome data. The linkage procedure 
differs for each data source and is performed by a trusted 
third party that is also responsible for anonymization.
Data and biomaterial handling
Clinical and patient-reported data are stored in a cen-
tral database, with data management performed by a 
UMCG-developed application named Utopia. This appli-
cation handles all necessary data management processes, 
including the integration of patient and laboratory data 
and the logistics for sending out study questionnaires. 
Utopia was developed using Microsoft C# and all data 
is stored on a Microsoft SQL Server. Authentication 
and authorization is via an Advantage Database Server. 
Full audit-trail support has been built into optimize data 
quality.
Imaging data of the OncoLifeS participants is exported 
from imaging devices (e.g. Computed Tomography (CT) 
or Magnetic Resonance Imaging (MRI) scanner) to the 
Picture Archiving and Communication System (PACS), 
which is a medical imaging technology providing eco-
nomical storage and convenient access to images from 
multiple modalities. The images are stored in PACS 
indefinitely. When required by a researcher, the images 
could be retrieved from PACS and copied to a secured 
environment, where researchers could access raw images 
for analysis using various software, such as Syngo.via, 
TeraRecon, etc.
Biomaterials are collected during clinical care. Blood 
samples are sent to the laboratory for both routine diag-
nostics and storage. Urine samples are collected by 
participants using a collection kit and are sent to the 
laboratory for storage. Fecal samples are also obtained 
via a collection kit, but the samples are delivered at the 
next follow-up visit. Tissue samples are collected in an 
operation theater during surgery or in an outpatient 
clinic during biopsy. Bone marrow aspirates are taken 
during routine procedures. All blood, fecal, and urine 
samples are labeled and sent to the central laboratory of 
the UMCG. The biomaterials are processed according to 
standard operating procedures and are stored accord-
ingly (Table 4). Long-term storage is guaranteed by a cen-
tralized freezing service offered by the LifeStore facility 
of the UMCG. Biomaterials are processed according to 
standard operating procedures and stored at the Depart-
ment of Pathology and Department of Hematology. Stor-
age devices (both freezers and liquid nitrogen storage) 
are 24/7 controlled/monitored by a professional service 
for quality control XiltriX. Quality control for biomate-
rials is covered by standard clinical practice and regular 
quality control is in progress for the biomaterials col-
lected since the OncoLifeS data-biobank was established.
Table 3 Data collected from  patient-completed 
questionnaires
Family history Questionnaire developed by 
OncoLifeS team
Cancer in first- and second-degree 
family members, kind of cancer




Malnutrition Universal Screening 
Tool (MUST)








Quality of life European Organisation for 
Research and Treatment of Can-
cer Quality of Life Questionnaire 
(30 questions) (EORTC QLQ-30)
Cancer Quality of Life EORTC Head 
and Neck module (35 questions) 
(EORTC QLQ-35)
Daily living activities Instrumental Activity of Daily Liv-
ing Questionnaire (IADL-Q)
Frailty Groningen Frailty Indicator (for 
patients 65 years and older)
G8 Questionnaire (for patients 
65 years and older)
Mental state status Geriatric Depression Scale (GDS-
15) questionnaire (only for 
patients with head and neck 
cancer)
Mini-Mental State Examination 
(MMSE; only for patients 65 years 
and older with head and neck 
cancer)
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Tumorous tissue samples and tissue adjacent to a 
tumor are transported to and handled by the Depart-
ment of Pathology. Tumor tissue undergoes standardized 
macroscopy to assess its suitability for biobanking, with 
emphasis placed on the need to ensure that biobanking 
does not interfere with primary diagnosis. The dedicated 
OncoLifeS samples are then coded separately from the 
clinical workflow and either formalin-fixed and paraffin 
embedded or kept as fresh frozen tissue at − 80 °C. These 
samples are stored indefinitely until needed for research 
or diagnostic purposes. In addition, the clinical paraf-
fin blocks are stored for 110 years by the Department of 
Pathology of the UMCG, and these are available for study 
purposes provided sufficient tissue remains for future 
diagnostic assessment. Bone marrow aspirates are trans-
ported to and handled by the Department of Haema-
tology. The aspirates for the biobank are used to isolate 
bone marrow cells, which are then frozen and stored in 
liquid nitrogen at − 196 °C.
Data and biomaterial access
Interested stakeholders can submit a research proposal to 
the coordinator of the OncoLifeS data-biobank and the 
involved tumor working group. The OncoLifeS scientific 
advisory board, which comprises representatives of each 
participating tumor working group, will then review the 
proposal. This board then advises the OncoLifeS steering 
committee on whether to approve requests for the use of 
clinical data and/or biomaterials. If approved, the project 
coordinator retrieves anonymized data or biomaterials 
from the OncoLifeS database or biobank. A protected 
workspace is provided for access to and analysis of data 
regarding cancer biomarkers, treatment response, and 
treatment effects for different patient outcomes, includ-
ing quality of life. This can also be used to give health care 
providers performance-related feedback and to monitor 
oncological care quality. If biomaterials are requested, 
agreements are made on how, where, and by whom they 
will be analyzed, and results from these analyses will 
be added to the workspace. On this workstation, the 
researcher will have access to the set of requested data. In 
addition, software is provided for data analysis.
Funding
The OncoLifeS initiative was established with funding 
from the UMCG and the Cancer Research Centre of the 
UMCG. The infrastructure for collection, processing, 
storing, and labeling of biomaterials is partly provided 
by the UMCG, with the ongoing costs of data collection 
and biological specimen storage covered by each par-
ticipating clinical department. External parties will also 
Table 4 The processing and storage of biomaterials in the OncoLifeS data-biobank
RT room temperature
Serum 10 mL serum clot tube (BD 367896) Centrifuge (10 min, 1300g, RT)—aliquot serum 5×, 
store at − 80 °C
EDTA-plasma + buffy coat (DNA) 10 mL K2-EDTA tube (BD 367525) Centrifuge (10 min, 1300g, RT), aliquot buffy coat 
1×, aliquot EDTA-plasma 5× store at − 80 °C
Heparin-plasma 10 mL Li-heparin tube (BD 367526)
2 × 10 mL Li-heparin tube (BD 367526)
Centrifuge (10 min, 1300g, RT), aliquot heparin-
plasma 5× store at − 80 °C
Monoculear cell isolation over lymphoprep, 100e6 
MNCs per vial, stored in liquid nitrogen
Plasma (for cell-free DNA) 2 × 8 mL tube (Streck 218997) Centrifuge (20 min, 1600g, RT), collect plasma, 
centrifuge (10 min, 16,000g, RT), aliquot cell-free 
DNA plasma 10×, store at − 80 °C
Whole blood (for DNA) 10 mL K2-EDTA tube (BD 367525) No processing, store tube at − 80 °C
Whole blood (for RNA) Paxgene tube (BD 762165) No processing, store tube at − 80 °C
Bone marrow 3 × 10 mL syringe with Na-heparin Isolation of mononuclear cells by density centrifu-
gation, controlled freezing of isolated mononu-
clear cells, store in liquid nitrogen
Feces swab in glycerol b Glycerol swab (Copan Custom kit M1016004) No processing, store tube with swab at − 80 °C
Feces 3 × 2.0 mL cryotubes (Greiner 122280) No processing, store cryotubes at − 80 °C
Urine 9.5 mL urine tube (BD 365000) Centrifuge (10 min, 1300g RT), aliquot urine 6×, 
store at − 80 °C
Tumor tissue (for paraffin embedding) Tissue fixed in formalin Tissue embedded in paraffin, store at RT
Tissue adjacent to a tumor (for frozen section) Tissue in tin Tissue in tin, store at − 80 °C
Tissue adjacent to a tumor (for paraffin embed-
ding)
Tissue fixed in formalin Tissue embedded in paraffin, store at RT
Healthy tissue (for frozen section) Tissue in tin Tissue in tin, store at − 80 °C
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be asked to cover our expenses and running costs when 
accessing.
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